InterVenn Biosciences has presented new data generated by the company’s novel, proprietary biomarker discovery platform, GlycoVision. The software analysed 575 retrospective samples and was able to achieve an overall sensitivity of 89% and specificity of 89% for predicting advanced adenoma (AA) and colorectal cancer (CRC).
“The data validates that we are on the right track toward defining a new era of pre-cancer detection for patients at risk of developing colon cancer,” said Erwin Estigarribia, InterVenn’s CEO. “Our unique glycoproteomic technology has achieved one of the industry’s highest level of sensitivity and specificity rates for AA and CRC seen to date using liquid biopsy and we expect to have a clinically validated test available to patients on the market later this year.”
“We’ve known that aberrant glycosylation events in colonic crypts and systemic circulation occur throughout the adenoma to carcinoma sequence. Simply, we’ve known for some time of the possibility to detect AA at the pre-cancer stage,” added Daniel Hommes, MD, PhD, gastroenterologist, and Chief Medical Officer at InterVenn. “We are thrilled to have data that validates the GlycoVision capabilities in a clinically meaningful way.”
Click below to share this article